Measuring lorazepam blood levels in adults treated for catatonia
Official title: Blood Concentration in Lorazepam and Treatment in Adult Catatonia
Run by University Hospital, Lille · NCT04530734 · Data updated 2026-11-12
This research will measure lorazepam blood levels in adults with catatonia to see if those levels relate to how well the medication works.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | January 1, 2020 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | May 22, 2026 |
| Trial ID | NCT04530734 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) diagnosed with catatonia according to DSM-5 who are receiving lorazepam and willing to provide blood samples are ideal candidates.
✕Probably not a fit
People under 18, pregnant patients, those not treated with lorazepam, or individuals unwilling to participate are unlikely to receive benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling adults diagnosed with catatonia per DSM-5 who are treated with lorazepam. Blood samples will be taken to measure lorazepam concentrations while clinical dosing and symptom response are recorded. No experimental interventions are given; treatment follows usual clinical care and researchers correlate blood levels with remission and side effects. The goal is to describe relationships between dose, blood concentration, and clinical outcome.
Why it matters
Potential benefit: If successful, findings could help clinicians personalize lorazepam dosing to improve remission rates and reduce side effects in catatonia.
How similar studies have gone: While lorazepam is a well-established effective treatment for catatonia, using measured blood concentrations to guide dosing is relatively untested and mostly unexplored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * catatonia according DSM-5 Exclusion Criteria: * Subject is less than 18 years of age * Subject is pregnant at the time of the study * Subject/legal guardian unwilling to participate in the study
Where it's running
-
Hôpital Fontan, CHU lille
Lille, France Recruiting
Study contacts
- Principal investigator: Ali AMAD, MD — University Hospital, Lille
- Study coordinator: Ali AMAD, MD
- Email: ali.amad@chru-lille.fr
- Phone: 03 20 44 44 60
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Treatment Response in Psychiatric Disorders Using Biological Markers
This study tests whether biological markers can predict which patients with psychiatric conditions will respond to treatment.
-
EEG microstates and inflammatory biomarkers in older adults with major depression receiving ECT
This study tests how ECT affects brain wave patterns and inflammatory markers in people 55 and older with major depression.
-
Catatonic syndrome in adults at Basurto Hospital: incidence, comorbidity, and short-term outcomes
This project will follow adults with catatonia treated at Basurto Hospital to see how often it happens, what other conditions they have, and how they respond to short-term treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.